PRIMA BIOMED LTD (ASX: PRR) - Interim Results - Clinical Trial for Ovarian Cancer Drug; Mr Eugene Kopp, Executive Chairman; Boardroomradio is pleased to announce that PRIMA BIOMED LTD (ASX: PRR) has published an audio file. The following presentation "PRR - Interim Results - Clinical Trial for Ovarian Cancer Drug" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Broadcaster: PRIMA BIOMED LTD (ASX: PRR)
Broadcast Title: PRR - Interim Results - Clinical Trial for Ovarian Cancer Drug
Broadcast Type: Audio stream
View the Audio stream for PRIMA BIOMED LTD (ASX: PRR) by clicking on the following links.
Display in Windows Media Player
Display in MP3 Player or Transfer to Portable Podcast Device
Computers set up for access to the Internet, including at least a 28.8k modem and sufficient memory and hard disk space to run Windows Media Player or Real Player, should be able to run BRR media files.
About Boardroom Media
Boardroom.Media is a new breed of media company that's equal parts publisher, content producer, and streaming media technology business. With a strong footing in capital markets, professional services and asset management, the company has been a leading provider of multimedia communication solutions for corporate Australia for more than a decade.
About Prima Biomed Ltd
Prima Biomed (ASX:PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac(tm) has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.
Related Industry Topics: